118 related articles for article (PubMed ID: 15001837)
21. A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro.
Gewirtz AM; Calabretta B
Science; 1988 Dec; 242(4883):1303-6. PubMed ID: 2461588
[TBL] [Abstract][Full Text] [Related]
22. Use of c-myb antisense oligonucleotides to increase the sensitivity of human colon cancer cells to cisplatin.
Funato T; Satou J; Kozawa K; Fujimaki S; Miura T; Kaku M
Oncol Rep; 2001; 8(4):807-10. PubMed ID: 11410788
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of c-Myb is associated with suppression of distant metastases in colorectal carcinoma.
Tichý M; Knopfová L; Jarkovský J; Pekarčíková L; Veverková L; Vlček P; Katolická J; Čapov I; Hermanová M; Šmarda J; Beneš P
Tumour Biol; 2016 Aug; 37(8):10723-9. PubMed ID: 26873484
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
Salatino M; Schillaci R; Proietti CJ; Carnevale R; Frahm I; Molinolo AA; Iribarren A; Charreau EH; Elizalde PV
Oncogene; 2004 Jul; 23(30):5161-74. PubMed ID: 15122317
[TBL] [Abstract][Full Text] [Related]
25. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of T-cell proliferation by a MYB antisense oligomer is accompanied by selective down-regulation of DNA polymerase alpha expression.
Venturelli D; Travali S; Calabretta B
Proc Natl Acad Sci U S A; 1990 Aug; 87(15):5963-7. PubMed ID: 1696013
[TBL] [Abstract][Full Text] [Related]
27. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
[TBL] [Abstract][Full Text] [Related]
28. Oligonucleotides complementary to c-myb messenger RNA inhibit growth and induce apoptosis in human Burkitt lymphoma cells.
Joshi S; Wu A; Verbik D; Algarra S; Bishop M; Pirruccello S; Iversen P; Jackson J; Kessinger M; Sharp J
Int J Oncol; 1996 Apr; 8(4):815-20. PubMed ID: 21544432
[TBL] [Abstract][Full Text] [Related]
29. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T
Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
[TBL] [Abstract][Full Text] [Related]
30. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
[TBL] [Abstract][Full Text] [Related]
31. Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules.
Opalinska JB; Kalota A; Gifford LK; Lu P; Jen KY; Pradeepkumar PI; Barman J; Kim TK; Swider CR; Chattopadhyaya J; Gewirtz AM
Nucleic Acids Res; 2004; 32(19):5791-9. PubMed ID: 15514112
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of proliferation by c-myb antisense RNA and oligodeoxynucleotides in transformed neuroectodermal cell lines.
Raschellà G; Negroni A; Skorski T; Pucci S; Nieborowska-Skorska M; Romeo A; Calabretta B
Cancer Res; 1992 Aug; 52(15):4221-6. PubMed ID: 1638535
[TBL] [Abstract][Full Text] [Related]
33. Myb expression is higher in malignant human colonic carcinoma and premalignant adenomatous polyps than in normal mucosa.
Ramsay RG; Thompson MA; Hayman JA; Reid G; Gonda TJ; Whitehead RH
Cell Growth Differ; 1992 Oct; 3(10):723-30. PubMed ID: 1445802
[TBL] [Abstract][Full Text] [Related]
34. Effects of phosphodiester and phosphorothioate antisense oligodeoxynucleotides on cell lines which overexpress c-myc: implications for the treatment of Burkitt's lymphoma.
Williams SA; Gillan ER; Knoppel E; Buzby JS; Suen Y; Cairo MS
Ann Oncol; 1997; 8 Suppl 1():25-30. PubMed ID: 9187425
[TBL] [Abstract][Full Text] [Related]
35. A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance.
Berg RW; Ferguson PJ; Vincent MD; Koropatnick DJ
Cancer Gene Ther; 2003 Apr; 10(4):278-86. PubMed ID: 12679800
[TBL] [Abstract][Full Text] [Related]
36. Growth inhibition and chemosensitization of human carcinoma cells by human serum albumin-coated liposomal antisense oligodeoxyribonucleotide against bcl-2.
Weecharangsan W; Lee RJ
Drug Deliv; 2012 Aug; 19(6):292-7. PubMed ID: 22931245
[TBL] [Abstract][Full Text] [Related]
37. Antisense src expression inhibits U937 human leukemia cell proliferation in conjunction with reduction of c-myb expression.
Waki M; Kitanaka A; Kamano H; Tanaka T; Kubota Y; Ohnishi H; Takahara J; Irino S
Biochem Biophys Res Commun; 1994 Jun; 201(2):1001-7. PubMed ID: 7516155
[TBL] [Abstract][Full Text] [Related]
38. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
[TBL] [Abstract][Full Text] [Related]
39. Technology evaluation: leukemia therapy, University of Pennsylvania.
Orr RM
Curr Opin Mol Ther; 1999 Jun; 1(3):399-403. PubMed ID: 11713805
[TBL] [Abstract][Full Text] [Related]
40. Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer.
Rait AS; Pirollo KF; Rait V; Krygier JE; Xiang L; Chang EH
Cancer Gene Ther; 2001 Oct; 8(10):728-39. PubMed ID: 11687896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
